… treatment for advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion
or exon 21 epidermal growth factor … mutations in different genes in a patient subgroup having …

… epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell
lung cancer (… (PFS-TKIs) between NSCLC patients with different EGFR double mutation …

… Conclusions: Our results demonstrated the distinct clinical characteristics of patients with …
In conclusion, our results revealed the distinct clinical characteristics of patients with MET …

… First-generation or second-generation epidermal growth factor … -mutation-positive advanced
non-small-cell lung cancer (NSCLC) … , these results may be biased due to different patients …

… epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have better clinical
benefits … In this study, we determined the treatment efficacies of different ICIs combinations. In …

… insights into the distinct biologic characteristics of … its clinical benefits.23, 24 In other
discussions for maintenance therapy, however, some pooled analyses indicated satisfactory results. …

… samples, 56 different rare EGFR mutations occurred. Information about the clinical outcome
was … Additionally, we report for the first time the clinical outcome after TKI treatment for 2 rare …

… Non-small cell lung cancer (NSCLC) harbouring EGFR exon … usually respond to epidermal
growth factor receptor–tyrosine … treatment responses to EGFR-TKIs in patients with different …

… benefits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to patients
at … Very young and very old patients with lung cancer have a distinct clinical presentation …

… 0.73 in patients with stage IIIb-IV non-small cell lung cancer … of lines of therapy, clinical
outcomes, and imaging studies. … We performed a separate analysis of 24 patients with tumors …